Plasma lipid trajectories improve prediction of future Alzheimer's disease
Authors:
- Haotian ZouHZHaotian Zou
- Rima Kaddurah-DaoukRKRima Kaddurah-Daouk
- Sheng LuoSLSheng Luo
- The Alzheimer'S Disease Neuroimaging InitiativeTIThe Alzheimer'S Disease Neuroimaging Initiative
- 6 April 2026
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (2) , 651-662
Abstract
Background: Early identification of individuals at elevated risk for Alzheimer's disease (AD) is critical for prevention. Blood-based biomarkers offer scalable alternatives to cerebrospinal fluid and imaging, but the prognostic value of longitudinal plasma lipid trajectories remains unclear. Objective: To evaluate whether multi-year plasma lipid trajectories improve prediction of AD conversion beyond demographic, clinical, genetic, and neuropsychological measures. Methods: We studied 1150 cognitively normal or mildly impaired Alzheimer's Disease Neuroimaging Initiative participants; 329 progressed to AD dementia over a mean follow-up of 2.3 years. Plasma lipidomics quantified 749 lipid species by high-resolution LC–MS. Trajectories were summarized using functional principal component analysis and related to time to conversion using covariate-adjusted Cox proportional hazards models. Predictive performance was assessed by concordance index and likelihood-ratio tests. Results: Cross-sectional lipid profiles modestly improved prediction beyond demographic and clinical covariates, and longitudinal lipid trajectories yielded small additional gains. Ether-linked triglycerides showed the strongest longitudinal associations with conversion, with TG(O-50:1) [NL-18:1] exhibiting the most robust signal. Neuropsychological measures provided substantially stronger discrimination, and lipid trajectories added limited value once cognitive information was included. Nevertheless, longitudinal lipid changes contributed consistent improvements in models without neuropsychological predictors, supporting their role as complementary blood-based markers in settings where standardized cognitive assessments are unavailable or impractical. Conclusions: Plasma lipid trajectories capture biologically relevant metabolic change associated with AD progression and provide complementary predictive information. Longitudinal lipidomic profiling may support early risk stratification and cohort enrichment when cognitive assessments are unavailable.Keywords
Funding Information
- National Health and Medical Research Council of Australia (2009965; 1197190)
- National Institute on Aging (AG064803; P30AG072958)
This publication has 27 references indexed in Scilit:
- Trajectory of plasma lipidome associated with the risk of late-onset Alzheimer's disease: a longitudinal cohort studyEBioMedicine, 2025
- APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studiesAlzheimer's & Dementia, 2022
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohortsThe Lancet Neurology, 2020
- Current state of Alzheimer’s fluid biomarkersActa Neuropathologica, 2018
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer DiseaseJAMA Neurology, 2017
- Metabolic network failures in Alzheimer's disease: A biochemical road mapAlzheimer's & Dementia, 2017
- The future of blood‐based biomarkers for Alzheimer's diseaseAlzheimer's & Dementia, 2013
- Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011